Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 6/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 3/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thiourea SCHEMBL6223777 | 0.87 | IDO1 (0.41) | IDO1HTTALDH1A1CYP17A1CYP11B1 | |
| SCHEMBL28945160 | 0.80 | DAO (0.44) | IDO1HTTALDH1A1CYP17A1CYP11B1 | |
| SCHEMBL25693776 | 0.78 | IDO1 (0.64) | IDO1 | |
| SCHEMBL16105820 | 0.78 | DAO (0.55) | HTTALDH1A1CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL3299911 | 0.78 | CYP17A1 (0.52) | HTTALDH1A1CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL28041389 | 0.76 | HTT (0.47) | HTTALDH1A1CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL6203927 | 0.76 | HTT (0.47) | HTTALDH1A1CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL126440 | 0.74 | HTT (0.45) | HTTALDH1A1CYP17A1CYP11B1CYP11B2 | |
| Iodide SCHEMBL2215328 | 0.74 | HTT (0.45) | HTTALDH1A1CYP17A1CYP11B1CYP11B2 | |
| Hydrochloric Acid SCHEMBL2823747 | 0.74 | HTT (0.45) | HTTALDH1A1CYP17A1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3664213-B1 | ELECTROLYTE FOR LITHIUM METAL BATTERY AND LITHIUM METAL BATTERY COMPRISING SAME | LG ENERGY SOLUTION LTD (KR) | 2023-09-13 | — | — | EP | claimed |
| EP-3547414-B1 | LITHIUM ELECTRODE AND LITHIUM SECONDARY BATTERY COMPRISING SAME | LG ENERGY SOLUTION LTD (KR) | 2023-09-13 | — | — | EP | claimed |
| US-11495824-B2 | Electrolyte for lithium metal battery and lithium metal battery comprising same | LG ENERGY SOLUTION, LTD. (KR) | 2022-11-08 | — | — | US | claimed |
| CN-110192294-B | Lithium electrode and lithium secondary battery comprising same | 株式会社LG新能源 | 2022-09-20 | — | — | CN | claimed |
| CN-111033864-B | Electrolyte for lithium metal battery and lithium metal battery comprising same | 株式会社LG新能源 | 2022-08-12 | — | — | CN | claimed |
| US-20200203759-A1 | ELECTROLYTE FOR LITHIUM METAL BATTERY AND LITHIUM METAL BATTERY COMPRISING SAME | LG CHEM, LTD. (KR) | 2020-06-25 | — | — | US | claimed |
| EP-3664213-A2 | ELECTROLYTE FOR LITHIUM METAL BATTERY AND LITHIUM METAL BATTERY COMPRISING SAME | LG Chem, Ltd. (KR) | 2020-06-10 | — | — | EP | claimed |
| US-20190319272-A1 | LITHIUM ELECTRODE AND LITHIUM SECONDARY BATTERY COMPRISING SAME | LG CHEM, LTD. (KR) | 2019-10-17 | — | — | US | claimed |
| EP-3547414-A2 | LITHIUM ELECTRODE AND LITHIUM SECONDARY BATTERY COMPRISING SAME | LG Chem, Ltd. (KR) | 2019-10-02 | — | — | EP | claimed |
| CN-110192294-A | LITHIUM ELECTRODE AND LITHIUM SECONDARY BATTERY COMPRISING SAME | 株式会社LG化学 | 2019-08-30 | — | — | CN | claimed |
| CN-113396364-B | Resist underlayer composition and method of forming pattern using the same | 三星SDI株式会社 | 2025-05-13 | — | — | CN | disclosed |
| CN-119472168-A | Resist underlayer composition and method of forming pattern using the same | 三星SDI株式会社 | 2025-02-18 | — | — | CN | disclosed |
| CN-119472167-A | Resist underlayer composition and method of forming pattern using the same | 三星SDI株式会社 | 2025-02-18 | — | — | CN | disclosed |
| US-20250053090-A1 | RESIST UNDERLAYER COMPOSITION AND METHOD OF FORMING PATTERNS USING THE COMPOSITION | SAMSUNG SDI CO., LTD. (KR) | 2025-02-13 | — | — | US | disclosed |
| US-20250053091-A1 | RESIST UNDERLAYER COMPOSITION, AND METHOD OF FORMING PATTERNS USING THE COMPOSITION | SAMSUNG SDI CO., LTD. (KR) | 2025-02-13 | — | — | US | disclosed |
| WO-2012097196-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AND USES AS ANTICANCER AGENTS | ACEA BIOSCIENCES INC. (US) | 2012-07-19 | — | — | WO | disclosed |
| EP-1686119-B1 | Pyrimidine-5-one derivatives as LDL-PLA2 inhibitors | SMITHKLINE BEECHAM PLC (GB) | 2009-07-29 | — | — | EP | disclosed |
| US-7482355-B2 | Asthma, antiallergens; rheumatoid arthritis and atherosclerosis; 2-(Benzylthio)-6-{[(1R)-2-hydroxy-1-methylethyl]amino}-4-pyrimidinol | ASTRAZENECA AB (SE) | 2009-01-27 | — | — | US | disclosed |
| EP-1539713-B1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2007-12-19 | — | — | EP | disclosed |
| US-20060004030-A1 | Pyrimidine derivatives as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004030-A1 | Pyrimidine derivatives as modulators of chemokine receptor activity | CXCR2, CXCR1, ACKR3 | IDO1 1820/4885HTT 4620/4885ALDH1A1 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.